By Maggie Fick

(Reuters) -GSK said on Wednesday it plans to invest $30 billion in research and development and supply chain infrastructure in the United States over the next five years, after U.S. President Donald Trump arrived in Britain for an unprecedented second state visit to seal investment deals.

The company said its new facilities will “bridge R&D and manufacturing across both the U.S. and UK, strengthening the two countries’ leadership in life sciences”.

London-based GSK said the investment includes $1.2 billion for the construction of a new factory at Upper Merion, Pennsylvania, to produce new medicines for respiratory disease and cancer, with construction planned to commence in 2026.

It will also invest in AI and advanced digital technology capabilities across GSK’s existing

See Full Page